摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

硫代嘌呤醇核糖核苷 | 54524-71-9

中文名称
硫代嘌呤醇核糖核苷
中文别名
——
英文名称
4-mercapto-1-β-D-ribofuranosyl-1H-pyrazolo<3,4-d>pyrimidine
英文别名
Thiopurinol ribonucleoside;1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7H-pyrazolo[3,4-d]pyrimidine-4-thione
硫代嘌呤醇核糖核苷化学式
CAS
54524-71-9
化学式
C10H12N4O4S
mdl
——
分子量
284.296
InChiKey
ZQNNJRBAYGYPHC-DAGMQNCNSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    644.3±65.0 °C(Predicted)
  • 密度:
    2.02±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -1.7
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    144
  • 氢给体数:
    4
  • 氢受体数:
    6

SDS

SDS:94c2ae8c0955c8a7ba7b821f5f11ce8b
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3
    • 4

反应信息

  • 作为反应物:
    参考文献:
    名称:
    吡唑并[3,4-d]嘧啶核糖核苷作为抗球虫药。3.4-[((芳基烯基)硫代]吡唑并[3,4-d]嘧啶的一些核苷的合成和活性。
    摘要:
    4-(烷硫基)-1H-吡唑并[3,4-d]嘧啶的核糖核苷已被证明是有用的抗球虫药[Krenitsky,TA; 骑乘,JL;GW科萨尔卡;Inmon,RB;赵安永; GB Elion;VS 威廉姆斯,RBJ Med。化学 1982,25,32。TA Krenitsky;Elion,GBUS专利4299 283,1981]。在那项研究中,不饱和的4-烯丙基硫代和4-巴甲基硫代衍生物(19和20)在体内对艾美球虫的活性比其饱和同类物更具活性。因此,合成了一些不饱和的(芳烷基)硫代衍生物,并作为抗球虫剂进行了研究。本研究中的新化合物(2至18)是通过将4-巯基-1-β-D-呋喃呋喃糖基-1H-吡唑并[3,4-d]嘧啶(1)烷基化制备的(1)方法。(E)-4-肉桂硫基衍生物(2)和5'-单磷酸酯(18)是体内对抗大肠杆菌的最具活性的化合物。在体内,在芳基部分(3至13)中具有取代基的类似物没有一个比
    DOI:
    10.1021/jm00364a024
  • 作为产物:
    描述:
    参考文献:
    名称:
    WO2023/52468
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • Pyrazolo[3,4-d]pyrimidine ribonucleosides as anticoccidials. 1. Synthesis and activity of some nucleosides of purines and 4-(alkylthio)pyrazolo[3,4-d]pyrimidines
    作者:Thomas A. Krenitsky、Janet L. Rideout、George W. Koszalka、Rosetta B. Inmon、Esther Y. Chao、Gertrude B. Elion、Victoria S. Latter、Raymond B. Williams
    DOI:10.1021/jm00343a007
    日期:1982.1
    cells than was 6. A series of 4-(alkylthio)-1-beta-D-ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidines was prepared from 4-mercapto-1-beta-D-ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidine (23) and various alkyl halides. The most effective compound in this series in vivo, 4-(ethylthio)-1-beta-D-ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidine (25), cleared chicks of the parasite at 50 ppm in the diet and was much less
    发现6-(甲基)-9-β-D-呋喃呋喃糖基-9H-嘌呤(6)对禽球菌,艾美球虫的毒性比体外对雏鸡肝宿主细胞的毒性更大,这促使类似物的合成和测试该化合物。揭示了β-D-呋喃呋喃糖基部分是重要的结构特征,嘌呤环中的几种类型的2-取代基降低了功效,对3-基和8-氮杂环的修饰也降低了效力。相反,吡唑并6(24)的[3,4-d]嘧啶类似物活性更高。而且,该类似物对宿主细胞的毒性比6种毒性低24倍。从4种制备了一系列的4-(烷基)-1-β-D-呋喃呋喃糖基-1H-吡唑并[3,4-d]嘧啶-巯基-1-β-D-呋喃呋喃糖基-1H-吡唑并[3,4-d]嘧啶(23)和各种烷基卤化物。
  • Pyrazolo pyrimidine riboside compounds, pharmaceutical compositions and
    申请人:Burroughs Wellcome Co.
    公开号:US04299823A1
    公开(公告)日:1981-11-10
    4-Substituted alkyl-1-.alpha.-D-ribofuransylpyrazole-(3,4-d) pyrimidines are active against coccidia in vivo and unlike the 4-methylthio analogue, are non-toxic. Methods for preparing and using the compounds, intermediates in the preparation and compositions of the compounds are also described.
    4-取代烷基-1-α-D-核糖呋喃吡唑-(3,4-d)嘧啶对体内球虫具有活性,与4-甲基类似物不具有毒性。还描述了制备和使用这些化合物的方法,制备过程中的中间体以及这些化合物的组成。
  • Analysis of the in vitro antitumor activity of novel purine-6-sulfenamide, -sulfinamide, and -sulfonamide nucleosides and certain related compounds using a computer-aided receptor modeling procedure
    作者:Vellarkad N. Viswanadhan、Arup K. Ghose、Naeem B. Hanna、Steven S. Matsumoto、Thomas L. Avery、Ganapathi R. Revankar、Roland K. Robins
    DOI:10.1021/jm00106a007
    日期:1991.2
    minimum energy conformation of (R,S)-2-amino-9-beta-D-ribofuranosylpurine-6-sulfinamide (sulfinosine, 5), an effective antileukemic agent in vivo, in the data set. The model fit the biological data with a standard deviation of 0.363, a correlation coefficient of 0.933 and a explained variance of 0.815. The method targeted a syn conformation as the probable active form and the 2'-OH, 5'-OH as well as
    最近使用培养的L1210细胞确定了21种新核苷的相对抗白血病活性,并通过计算机辅助受体建模方法(REMOTEDISC)分析了与结构相关的功效(Ghose,AK; et al.J.Med。 Chem.1989,32,746)。该算法可以归类为3D-QSAR方法,包括以下步骤:从活性化合物的低能构象中选择参考结构;自动叠加其他化合物的低能构象,从而使基于原子的物理化学性质具有最大的匹配(或重叠);从重叠分子的原子位置构造结合位点腔;反向逐步回归分析确定部位腔不同区域各种理化性质的相对重要性。该模型基于数据集中的有效体内抗白血病药物(R,S)-2-基-9-β-D-呋喃呋喃糖基嘌呤-6-亚磺酰胺(亚磺酰胺,5)的最小能量构象。该模型拟合的生物学数据的标准偏差为0.363,相关系数为0.933,解释方差为0.815。该方法以顺式构象为可能的活性形式为目标,嘌呤环的2'-OH,5'-OH以及C2-N
  • Substituted pyrazolo pyrimidine riboside compounds, pharmaceutical
    申请人:Burroughs Wellcome Co.
    公开号:US04299824A1
    公开(公告)日:1981-11-10
    4-Alkenylthio-1-.beta.-D-ribofuranosylpyrazolo[3,4-d]-pyrimidines are active against coccidia in vivo, and unlike the 4-methylthio analogue, are non-toxic. Methods for the preparation and use of the compounds, intermediates in the preparation and formulations of the compounds are also described.
    4-基-1-β-D-核糖呋喃吡唑并[3,4-d]-嘧啶类化合物在体内对球虫有活性,并且与4-甲基基类似物不具有毒性。本文还描述了制备和使用这些化合物的方法,制备这些化合物的中间体以及这些化合物的配方。
  • 4-Substituted thio-1-beta-D-ribofuranosylpyrazolo(3,4-D) pyrimidines, processes for their preparation, pharmaceutical formulations and medical uses
    申请人:THE WELLCOME FOUNDATION LIMITED
    公开号:EP0021293A2
    公开(公告)日:1981-01-07
    Compounds of formula (I) or organic or 51-phosphate esters and salts thereof wherein n has a value from 1 to 6 and R is a methyl, substituted or unsubstituted phenyl, phenoxy or phenylthio group or an alkoxy or alkylthio group or a group -C=C-R5 or -(CH= CH)MR5 wherein R5 is a substituted or unsubstituted phenyl group and m has the value 1 or 2, are active against coccidia. Processes for the production of such compounds by chemical and enzymatic methods, intermediates in the processes and pharmaceutical formulations and dosage regimes are also described.
    式(I)化合物或其有机或 51-磷酸和盐,其中 n 的值为 1 至 6,R 为甲基、取代或未取代的基、基或基或烷基或烷基或基团-C=C-R5 或-(CH=CH)MR5,其中 R5 为取代或未取代的基,m 的值为 1 或 2,具有抗球虫活性。 还描述了通过化学和酶法生产此类化合物的工艺、工艺中的中间体以及药物制剂和剂量方案。
查看更多

同类化合物

硫代嘌呤醇核糖核苷 硝基苄基硫代间型霉素 别嘌呤醇核糖苷 [3,4-二乙酰氧基-5-(5-甲硫基-2,4,8,9-四氮杂双环[4.3.0]壬-2,4,7,10-四烯-9-基)四氢呋喃-2-基]甲基乙酸酯 6-氮杂卡德勾霉素 6-氨基别嘌呤醇核糖甙 4-氨基-3-苄基-1H-吡唑并[3,4-d]嘧啶-1-β-D-呋喃核糖 1 beta-呋喃核糖基-4-(甲硫基)吡唑并(3,4-d)嘧啶 1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidine-4-sulfenamide 4-amino-3-(3''-hydroxy-1''-propynyl)-1-(2',3',5'-tri-O-benzoyl-β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine 1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)pyrazolo<3,4-d>pyrimidine-4-carbonitrile 1-(2',3',5'-Tri-O-acetyl-β-D-ribofuranosyl)-3-cyano-4-methylmercaptopyrazolo<3,4-d>pyrimidine Acetic acid (2R,3R,4R,5R)-4-acetoxy-5-acetoxymethyl-2-(4-methanesulfonyl-pyrazolo[3,4-d]pyrimidin-1-yl)-tetrahydro-furan-3-yl ester 8-aza-7-deaza-7-[(5,7-di-tert-butylbenzoxazol-2-yl)ethynyl]adenosine (2R,3R,4S,5R)-2-{4-[(E)-3-(2,4-Dichloro-phenyl)-allylsulfanyl]-pyrazolo[3,4-d]pyrimidin-1-yl}-5-hydroxymethyl-tetrahydro-furan-3,4-diol 3-(methylthio)-1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidin-4(5H)-one 3-chloro-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine 1-(2,3,4,6-Tetra-O-benzyl-β-D-glucopyranosyl)-1,5-dihydro-4H-pyrazolo-<3,4-d>pyrimidin-4-on (2R,3R,4S,5R)-2-{4-[(E)-3-(3,4-Dichloro-phenyl)-allylsulfanyl]-pyrazolo[3,4-d]pyrimidin-1-yl}-5-hydroxymethyl-tetrahydro-furan-3,4-diol 1-(2,3,4,6-Tetra-O-benzyl-β-D-glucopyranosyl)-1H-pyrazolo<3,4-d>pyrimidin-4-amin (2S,3R,4S,5R)-2-(4-amino-3-phenylpyrazolo[3,4-d]pyrimidin-1-yl)-5-hydroxymethyltetrahydrofuran-3,4-diol 1-(β-D-arabinofuranosyl)-1H-pyrazolo<3.4-d>pyrimidin-4-one 1-(2,3,5-tri-O-benzyl-β-D-arabinofuranosyl)-1H-pyrazolo<3.4-d>pyrimidin-4-one (2R,3R,4S,5R)-2-(4-Dihexylamino-pyrazolo[3,4-d]pyrimidin-1-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol 4-(butylamino)-1-β-D-ribofuranosyl-1H-pyrazolo<3,4-d>pyrimidine 6-O-ethylinosine 1-(β-D-Ribofuranosyl)-3-carbamoyl-4,6-dimethylmercaptopyrazolo<3,4-d>pyrimidine 1-N-ethylinosine 6-amino-3-methyl-1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidin-4(5H)-one 1-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)-3-thiocarbamoyl-4,6-dimethylmercaptopyrazolo<3,4-d>pyrimidine 1-(β-D-Ribofuranosyl)-4-amino-6-methylmercapto-3-carbamoylpyrazolo<3,4-d>pyrimidine 1-(β-D-Ribofuranosyl)-3-carbamoyl-4-amino-6-methylsulfonylpyrazolo<3,4-d>pyrimidine 6-Methylthio-4(5H)-oxo-1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidine 4,6-Dimethylthio-1-α-(2,3,5-tri-O-acetyl-D-xylofuranosyl)pyrazolo<3,4-d>pyrimidine 1-(β-D-Ribofuranosyl)-3-carbamoyl-4,6-diaminopyrazolo<3,4-d>pyrimidine 6-amino-4-methoxy-1-α-D-arabinofuranosylpyrazolo<3,4-d>pyrimidine 6-Methylthio-4(5H)-oxo-1-α-D-xylofuranosylpyrazolo<3,4-d>pyrimidine 6-Amino-4(5H)-oxo-1-α-D-xylofuranosylpyrazolo<3,4-d>pyrimidine N-<(6-amino-1-β-D-ribofuranosyl-4,5-dihydro-4-oxopyrazolo<3,4-d>pyrimidin-3-yl)carbonyl>glycine amide 4,6-Dimethylthio-1-α-D-xylofuranosylpyrazolo<3,4-d>pyrimidine 4,6-dimethylthio-1-α-D-arabinofuranosylpyrazolo<3,4-d>pyrimidine 4-methoxy-6-methylsulphonyl-1-α-(2,3,5-tri-O-acetyl-D-arabinofuranosyl)pyrazolo<3,4-d>pyrimidine 4-amino-6-methylthio-1-α-D-arabinofuranosylpyrazolo<3,4-d>pyrimidine 4-amino-6-methylsulphonyl-1-α-D-arabinofuranosylpyrazolo<3,4-d>pyrimidine 4-acetamido-6-methylsulphonyl-1-α-(2,3,5-tri-O-acetyl-D-arabinofuranosyl)pyrazolo<3,4-d>pyrimidine 4-amino-6-methoxy-1-α-D-arabinofuranosylpyrazolo<3,4-d>pyrimidine 4.6-Diamino-1-β-ribofuranosyl-1H-pyrazolo<3.4-d>pyrimidin 1-(N-Methyl-β-D-ribofuranuronamidosyl)-1H-pyrazolo<3,4-d>pyrimidin-4-amin 4-methoxy-6-methylthio-1-α-(2,3,5-tri-O-acetyl-D-arabinofuranosyl)pyrazolo<3,4-d>pyrimidine 1-β-D-ribofuranosyl-4(5H)-thioxopyrazolo<3,4-d>pyrimidine-3-carbonitrile